Maxime Dely: Therapeutic Apheresis – How Do You Know When You Can’t Wait Any Longer?
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
“Therapeutic Apheresis: How do you know when you can’t wait any longer?
3 clinical criteria to decide on Therapeutic Apheresis
Therapeutic apheresis is neither an automatic reflex nor a last-resort treatment by default. The right indication relies on a structured clinical reasoning, which can be summarized into three key criteria.
1. A clearly identifiable circulating pathogenic target
Apheresis makes sense when the disease mechanism involves a blood-borne factor that can be mechanically removed:
– autoantibodies (TTP, myasthenia gravis, Goodpasture syndrome)
– immune complexes (severe lupus)
– abnormal cells (leukostasis in acute leukemias)
– lipoproteins (homozygous familial hypercholesterolemia)
Without a clearly identified circulating target, the expected benefit becomes questionable.
2. Acute or rapidly progressive clinical severity
Myasthenic crisis with respiratory failure, thrombotic thrombocytopenic purpura, progressive Guillain–Barré syndrome, antibody-mediated graft rejection…
In these situations, apheresis is a life-saving or organ-saving emergency intervention.
3. A mismatch between clinical urgency and the onset of action of standard therapies
Immunosuppressive drugs, IVIg, or chemotherapy may be effective — but sometimes too slow.
Therapeutic apheresis allows an immediate reduction of the pathogenic burden, stabilizing the patient and creating a therapeutic window.
Deciding on apheresis is not about ticking boxes on a list of indications. It is about integrating pathophysiology, clinical severity, and timing, through close multidisciplinary collaboration.
When properly indicated, apheresis is not a technical luxury — it is a strategic clinical tool.”
Find more posts featuring Maxime Dely on Hemostasis Today.
-
Jan 7, 2026, 08:50Fahad Khaliq on When is Ticagrelor Preferred Over Other Antiplatelets
-
Jan 7, 2026, 06:41Zain Khalpey on AI Driven Risk Prediction for Optimization of Anticoagulation in LVAD
-
Jan 7, 2026, 05:47Michael Makris: The Wakley Prize Essay Published in Today’s Lancet is an Excellent Read
-
Jan 7, 2026, 05:36Pierre F Sabouret Shares A Study on the Risk of Cardiovascular Death in SIDs
-
Jan 7, 2026, 05:15Glaivy Batsuli Reflects on ASH25
-
Jan 7, 2026, 05:04Heghine Khachatryan on VWD: A Landmark in the History of Hematology
-
Jan 6, 2026, 13:39JAMA Neurology: No Added Benefit of Dual Therapy After Ischemic Stroke in Case of AFib
-
Jan 6, 2026, 10:10This is Fantastic: Shirley D’Sa on Transfusion-Free Christmas Milestone for 𝛃-Thalassaemia Patient at UCLH
-
Jan 6, 2026, 09:53Hamideh Yadegari: Coagulation–Inflammation Crosstalk: Mechanisms, Pathways, and Clinical Implications